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The g-aminobutyric acid (GABA) transporter GAT-1 is
located in nerve terminals and catalyzes the electro-
genic reuptake of the neurotransmitter with two sodium
ions and one chloride. We now identify a single tyrosine
residue that is critical for GABA recognition and trans-
port. It is completely conserved throughout the super-
family, and even substitution to the other aromatic
amino acids, phenylalanine (Y140F) and tryptophan
(Y140W), results in completely inactive transporters.
Electrophysiological characterization reveals that both
mutant transporters exhibit the sodium-dependent
transient currents associated with sodium binding as
well as the chloride-dependent lithium leak currents
characteristic of GAT-1. On the other hand, in both mu-
tants GABA is neither able to induce a steady-state
transport current nor to block their transient currents.
The nontransportable analog SKF 100330A potently in-
hibits the sodium-dependent transient in the wild type
GAT-1 but not in the Y140W transporter. It partly blocks
the transient of Y140F. Thus, although sodium and chlo-
ride binding are unimpaired in the tyrosine mutants,
they have a specific defect in the binding of GABA. The
total conservation of the residue throughout the family
suggests that tyrosine 140 may be involved in the ligand-
ing of the amino group, the moiety common to all of the
neurotransmitters.
High affinity sodium-coupled neurotransmitter transport
plays a major role in the maintenance of low synaptic levels of
the transmitter (for a review, see Ref. 1). Direct proof of this
has been obtained recently for the dopamine transporter, using
homozygous mice in which this transporter was disrupted (2).
GAT-1 is a GABA1 transporter that was reconstituted, purified
to homogeneity (3), and cloned (4). It is the prototype of a large
superfamily of sodium- and chloride-dependent transporters of
neurotransmitters. This includes transporters norepinephrine,
dopamine, serotonin, and glycine as well as several additional
GABA transporters (for a review, see Ref. 5). GAT-1 catalyzes
the electrogenic transport of GABA with one chloride and two
sodium ions (6–8).
Using site-directed mutagenesis we have attempted to iden-
tify amino acid residues of GAT-1 involved in substrate bind-
ing. Since GABA is a zwitterionic molecule and the cosub-
strates are charged species, we have changed the charged and
conserved residues likely to be located in the membrane. This
revealed that arginine 69 is critical for transport (9). Although
we also identified a critical negatively charged residue, gluta-
mate 101 (10), it is not clear that it is located in the membrane.
Other residues that may interact with positively charged sub-
strates, such as sodium ions or the amino group of the neuro-
transmitter, are aromatic amino acids, which could do so by
virtue of their p electrons (11–13). In a previous study we have
modified the tryptophan residues of GAT-1 thought to be lo-
cated in the membrane (14). Even though two important tryp-
tophans were identified, it is now clear that they are not di-
rectly involved in substrate binding (15).2
In this study we have modified the tyrosine residues of
GAT-1, which are thought to be located in the membrane and
are conserved throughout the superfamily. We have identified
one residue, tyrosine 140, which is critical for transport and
does not tolerate replacement to other aromatic residues.
Transporters in which the residue is replaced by phenylalanine
(Y140F) or tryptophan (Y140W) still exhibit sodium and chlo-
ride binding but appear to be impaired selectively in the bind-
ing of GABA. The stringent conservation of the tyrosine sug-
gests that it may interact with a moiety common to all
substrates of the family, namely the amino group.
EXPERIMENTAL PROCEDURES
Materials
[3H]GABA (47.6 Ci/mmol) was obtained from the Nuclear Research
Center (Negev, Israel) and D,L-[3,4-3H]nipecotic acid (40 Ci/mmol) was
from Amersham. SFK 100330A and the recombinant vaccinia/T7 virus
vTF7/3 were generous gifts of Dr. W. Blondinell (Smith Kline Beecham)
and Dr. B. Moss (National Institutes of Health), respectively. Molecular
mass markers were from Pharmacia Biotech Inc. Solutions of acrylam-
ide/bisacrylamide were obtained from Bio-Rad. Restriction enzymes
were from New England Biolabs Inc. and Boehringer Mannheim. T4
polynucleotide kinase, T4 DNA polymerase, T4 DNA ligase, and the
transfection reagent DOTAP were also from Boehringer Mannheim.
Sequenase version 2.0 kits were obtained from U. S. Biochemical Corp.,
and kits for plasmid DNA preparation were from QIAGEN Inc.
[35S]dATPaS and EXPRE35S35S protein-labeling mixture (1,000 Ci/
mmol) were from Du Pont NEN. Tissue culture medium, serum, and
antibiotics were from Biological Industries (Kibbutz Beit HaEmek,
Israel). PCOOH, a peptide located in the carboxyl terminus of GAT-1
(residues 571–586, IQPSEDIVRPENGPEQ), was synthesized by Dr.
Lea Goldberg (Weizmann Institute, Rehovot, Israel) on an Applied
Biosystems model 430A peptide synthesizer. The antibody against
PCOOH was raised in a rabbit as described (16).
Methods
Site-directed Mutagenesis—This was performed using the method of
Kunkel et al. (17) as described (14). Mutations were confirmed by DNA
sequencing and were subcloned into wild type using pairs of unique
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restriction enzymes cutting the cDNA on either side of the mutation.
The subcloned mutant cDNAs were then sequenced from each direction
between the two restriction sites.
Cell Growth and Expression—HeLa cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum, 200
units/ml penicillin, 200 mg/ml streptomycin, and 2 mM glutamine. In-
fection with recombinant vaccinia/T7 virus vTF7-3 (18) and subsequent
transfection with plasmid DNA, GABA transport (19), and immunopre-
cipitation (20) were done as published previously. Protein was deter-
mined as described by Bradford (21). Sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis was as described by Laemmli (22) using a 4%
stacking and 10% separating gel. Size standards (Pharmacia Biotech
Inc.) were run in parallel and visualized by Coomassie Blue staining.
Reconstitution of transport was done as follows. For each experiment
infected/transfected cells from two large wells (35-mm diameter) were
used for each mutant. They were washed twice with 1 ml of phosphate-
buffered saline and taken up in a small volume of phosphate-buffered
saline using a rubber policeman. To 35 ml of this suspension were added
(in this order) 15 ml of 0.1 M KPi (pH 7.5) and 10 ml of 20% cholic acid
(neutralized by NaOH). After 10 min of incubation on ice, the mixture
was reconstituted with asolectin/brain lipids using spin columns, and
transport was measured exactly as described (23).
Electrophysiology—The cDNAs encoding GAT-1 and the mutants
Y140F and Y140W were subcloned in the oocyte expression vector pOG,
which contains a 59-untranslated Xenopus b-globin sequence and a
39-poly(A) signal). Capped cRNAs transcribed from these constructs
were injected into stage V–VI Xenopus oocytes (50 ng/oocyte), and
membrane currents were recorded 2–3 days later (15, 24). Recording
solution (Ringer) contained 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM
CaCl2, and 5 mM HEPES (pH 7.4). In substitution experiments sodium
ions were replaced with equimolar choline or lithium, and chloride was
replaced by acetate. Two microelectrode voltage clamp recordings were
performed at 22 °C with a Geneclamp 500 interfaced to an IBM-com-
patible PC using a Digidata 1200 A/D controlled using the pCLAMP 6.0
program suite (Axon Instruments). The data were acquired at 2 kHz
and low pass filtered at 1 kHz. Microelectrodes were filled with 3 M KCl
solution and had resistances of ,1 megohm. In Cl2 substitution exper-
iments, a 3 M KCl-agar bridge connected the recording chamber to a 3
M KCl reservoir containing an Ag/AgCl electrode. Records shown are
typical and representative of experiments done with four or five inde-
pendent oocytes. Blockade by SKF 100330A was reversible but required
extensive washout periods (.5 min).
RESULTS
Identification of a Tyrosine Residue Critical for GABA Trans-
port—Fig. 1 shows the position of the 12 conserved tyrosine
residues, predicted to be located in the membrane according to
the theoretical topological model (4). Tyrosine residues 72, 86,
140, 309, and 475 located in respective transmembrane do-
mains I, II, III, VI, and X, are totally conserved in all known
members of the superfamily. The others are mostly aromatic in
the majority of the transporters. Using site-directed mutagen-
esis each of these residues was changed to serine. After the
mutations were verified by sequencing, the mutant cDNAs
were expressed in HeLa cells using the recombinant vaccin-
ia/T7 virus (18) as described (19). The results of sodium-de-
pendent [3H]GABA transport of the mutants are shown in Fig.
2. Replacement of each of the five residues 241, 246, 248, 296,
and 432 by serine results in transporters that exhibit signifi-
cant activity. Because of the very different nature of the side
chains of tyrosine and serine, we conclude that these five res-
idues are not essential for sodium- and chloride-dependent
GABA transport. It is of interest to note that all of the fully
conserved tyrosines are included in the remaining seven in
which replacement by serine severely compromises transport.
Each of these seven tyrosines was then also changed to the
other aromatic amino acids, phenylalanine and tryptophan.
The results are shown in Fig. 3. It can be seen that in six out of
the seven cases at least one of the aromatic replacement mu-
tants exhibits significant transport of [3H]GABA. Only in the
case of tyrosine 140 are both replacement mutants, Y140F and
Y140W, totally devoid of any detectable transport activity.
These mutations were subcloned back into the wild type back-
ground. Sequencing of the subcloned mutant cDNA fragments
from both sides was then performed to ensure that only the
indicated mutation had occurred without any additional
changes. Reexamination of the subcloned Y140F and Y140W
transporters showed that their phenotype, lack of detectable
sodium-dependent [3H]GABA transport, was maintained (not
shown). D,L-[3,4-3H]Nipecotic acid, a ring constrained analog of
GABA, is also transported by wild type GAT-1 in a sodium-de-
pendent fashion but not by Y140F- and Y140W-GAT-1 trans-
porters (data not shown).
The impaired transport of the mutants is not due to lower
transporter levels. Wild type GAT-1 and Y140F- and Y140W-
GAT-1 mutant transporters were expressed in HeLa cells, la-
beled with [35S]methionine, and immunoprecipitated by an
FIG. 1. Hypothetical secondary structure of the GAT-1 transport protein. Putative transmembrane segments are depicted as rectangles.
The indicated tyrosines have been modified by site-directed mutagenesis.






















antibody raised against a peptide located in the carboxyl ter-
minus of GAT-1. The transporter is detected in three major
forms: a monomer running as a band of ;65 kDa, a more
abundant dimer, and a high molecular mass aggregate (Fig. 4,
lane 1). In addition, a faster running minor band can be visu-
alized (Fig. 4) which corresponds to the transporter that has
not been glycosylated (20). No transporter is detected in HeLa
cells transfected with the vector alone (Fig. 4, lane 2). In con-
trast each of the two mutants, Y140F- and Y140W-GAT-1,
express high transporter levels (Fig. 4, lanes 3 and 4).
Because the mutants still produce normal transporter levels
it is possible that they are targeted inefficiently to the plasma
membrane. One would expect that cells expressing a mistar-
geted mutant transporter that is intrinsically active would
have cryptic transport activity. Detergent extraction of the cells
expressing such a transporter followed by reconstitution of the
solubilized proteins is likely to yield transport activity even if
they were originally residing in internal membranes. In fact,
such cryptic transport activity has been observed using this
assay with some mutants of GAT-1 (14, 25) and of the gluta-
mate transporter GLT-1 (26). Both mutant transporters re-
main completely void of activity after solubilization and recon-
stitution, in contrast to the wild type (data not shown).
Sodium and Chloride Binding to Y140F- and Y140W-GAT-
1—The above results indicate that mutant transporters Y140F
and Y140W have an intrinsic defect in the transport process
itself. We used an electrophysiological approach monitoring
partial reactions of the translocation cycle to pinpoint the de-
fect in the mutant transporters. One such reaction is the bind-
FIG. 4. Immunoprecipitation of wild type and mutant trans-
porters. HeLa cells were infected with the vaccinia/T7 recombinant
virus and transfected with the indicated cDNAs. After labeling with
[35S]methionine, cells were immunoprecipitated as described under
“Experimental Procedures.” The cDNA used to transfect was pT7-
GAT-1 (wild type, lane 1), vector alone (pBluescript SK2), lane 2),
Y140F (lane 3), or Y140W (lane 4).
FIG. 2. Transport activity of GAT-1
and mutant transporters in which ty-
rosine has been changed to serine.
HeLa cells were infected with recombi-
nant virus and transfected with pBlue-
script containing wild type (WT) or the
indicated mutants. Sodium-dependent
transport of [3H]GABA was performed as
described under “Experimental Proce-
dures.” Results are given as a percent of
wild type transport activity. Each bar is
the mean 6 S.E. of three to five different
experiments.
FIG. 3. Transport activity of GAT-1
and mutant transporters in which ty-
rosine has been changed to phenyl-
alanine and tryptophan. Results of the
sodium-dependent [3H]GABA transport
of the indicted mutants are given as a
percentage of the value of the wild type
(WT). Dark bars, mutations to phenylala-
nine; light bars, mutations to tryptophan.






















ing of sodium to the transporter, which can be monitored as a
sodium-dependent transient current observed after changing
the membrane potential (8, 15). This is exemplified in Fig. 5.
Oocytes expressing GAT-1 are held at a membrane potential of
230 mV in a sodium-containing medium. Subsequently the
membrane potential is jumped to a range of potentials varying
from 130 mV (Fig. 5A, upper trace) to 2120 mV (Fig. 5A, lower
trace). In oocytes expressing GAT-1, slow current relaxations
(time constants 70–130 ms) were observed following voltage
jumps, and these transient currents were greatly attenuated by
replacement of sodium with choline (Fig. 5A). These currents
are distinct from the rapidly decaying membrane capacitance
and are presumed to reflect transporter-mediated charge move-
ments associated with sodium binding (8, 15). Uninjected con-
trol oocytes did not display this slow sodium-dependent relax-
ation (Fig. 5B). Analogous sodium-dependent transient
currents were also observed in oocytes expressing the GAT-1
mutant Y140F and Y140W transporters (Fig. 5, C and D). In
oocytes expressing the mutant transporter Y140W, the sodium-
dependent transient current displayed slightly faster relax-
ation, with time constants ranging from 40–80 ms, whereas
the relaxation times of the Y140F mutant were unchanged
from wild type GAT-1.
In addition to sodium, chloride ion also interacted with both
the mutant wild type transporters. As reported previously (15),
wild type GAT-1 exhibits a GABA-independent and lithium-de-
pendent leak current that is increased by the presence of chlo-
ride ions (Fig. 6). An analogous lithium-dependent current was
observed in oocytes expressing the Y140F and Y140W mutant
transporters, and this current was increased in the presence of
chloride (Fig. 6). These results demonstrate that the mutant
transporters Y140F and Y140W retain both the lithium-de-
pendent leak current and the ability to bind chloride seen in
the wild type transporter.
Interaction of GABA and Uptake Blockers with Wild Type
and Mutant GAT-1—The sodium-dependent charge move-
ments induced by voltage jumps are inhibited by nontrans-
ported GABA analogs (8). This is exemplified for wild type
GAT-1 (Fig. 7A), which shows the transient current blocked by
SKF 100330A at 30 mM, a concentration 2 orders of magnitude
above its apparent Ki for blocking GABA transport (27). Con-
sistent with this, 30 mM SKF 100330A blocked 98.0 6 0.4% (n 5
3) of the off charge movement induced by stepping from 2120
to 230 mV (Fig. 8A). In contrast, SKF 100330A was signifi-
cantly less efficacious at blocking the charge movements in the
FIG. 6. Chloride-dependent lithium leak currents mediated by
wild type (wt) and mutant transporters. Steady-state lithium-in-
duced currents (obtained by subtraction of the response in sodium) in
representative oocytes expressing wild type and mutant transporters
were recorded at the indicated potentials, in the presence or absence of
chloride (acetate substitution). Similar results were obtained in three or
four oocytes.
FIG. 5. Sodium-dependent transient currents mediated by wild type (wt) and mutant transporters. Transient currents were recorded
in the presence and the absence of sodium (choline substitution) in oocytes expressing wild type (panel A) and Y140F (panel C) and Y140W (panel
D) transporters as well as in noninjected oocytes (panel B). The voltage was jumped from a holding potential of 230 mV to potentials ranging from
2120 to 130 mV. The duration of each pulse was 500 ms. Following reperfusion with sodium solutions after choline, complete recovery of the
transient currents was observed (data not shown).






















Y140F transporter, 33.9 6 7.2% (n 5 3), as illustrated in Figs.
7 and 8, panels C. Increasing the concentration of the inhibitor
to 100 mM blocked 63% of the charge movement (n 5 2). This
difference in potency was even greater in the Y140W mutant,
in which 100 mM SKF 100330A blocked only 1.9 6 1.0% (n 5 4)
of the charge movement (Figs. 7 and 8, panels D).
GABA itself, when added in a sodium chloride-containing
medium, induces a steady-state transport current in the wild
type (Fig. 9A). In agreement with the tracer flux data (Fig. 3),
GABA is not able to induce a transport current in the mutants
(Fig. 9, B and C). Moreover, it is not even capable of inhibiting
a transient current (Fig. 9, B and C). Thus, not only is GABA
not transported by the mutant transporters, it is not even able
to bind to them.
DISCUSSION
In this paper we have identified a tyrosine residue, which is
critical for sodium- and chloride-dependent GABA recognition
and transport. Out of the 12 conserved residues, tyrosine 140 is
the only one that does not tolerate replacement to either phe-
nylalanine or tryptophan (Fig. 3). This is neither due to re-
duced synthesis (Fig. 4) nor to reduced targeting (Figs. 5–7).
The electrophysiological (Figs. 5–8) data clearly show the pres-
ence of sodium-dependent transient currents and chloride-de-
pendent leak currents of lithium, strongly indicating that the
mutant transporters are localized in the plasma membrane and
that the structural elements critical for forming the trans-
porter pore are intact. They strongly point to a defective GABA
binding in the mutants. Not only are GABA and nipecotic acid
not transported, GABA is not able to suppress the capacitative
transient sodium current in Y140F- and Y140W-GAT-1 as it
does in the wild type (Fig. 9). This is also supported by the total
inability of SKF 100330A to suppress the clearly existent so-
dium transient in Y140W-GAT-1 (Figs. 5D, 7D, and 8D). This
compound is a derivative of the GABA analog guvacine to
which via the nitrogen atom a diphenylbutenyl group has been
attached (27). The observation that the blocker still has some
effect, albeit diminished, on the transient current of Y140F-
GAT-1 indicates that the mutation does not cause a sterical
alteration of the binding pocket for GABA. Although far from
clear, its limited ability to interact with Y140F, but not with
Y140W-GAT-1, could perhaps be due to an interaction of one of
the phenyl groups of SKF 100330A with the introduced phenyl-
FIG. 7. Currents blocked by SKF 100330A mediated by wild type (WT) and mutant transporters. Difference records are shown
representing SKF 100330A (30 mM); sensitive currents were obtained by subtraction of currents recorded in the presence of blocker at potentials
between 130 and 2120 mV from control currents. Superfusion of oocytes expressing wild type (panel A), Y140F (panel C), or Y140W (panel D)
transporters was done in a sodium-containing medium. Records for noninjected oocytes are also shown (panel B). The conditions were similar to
those in Fig. 5.
FIG. 8. SKF 100330A effects on the off charge movements elic-
ited by stepping back from 2120 to 230 mV. The same cells were
used in Fig. 7. The transient currents obtained by stepping back from
2120 to 230 mV in the presence or absence of 30 mM SKF 100330A are
shown.






















alanine at the 140 position.
In view of the total conservation of the tyrosine residue in the
superfamily of transporters, it is tempting to speculate that it
interacts with a structural element common to all of the trans-
ported solutes. This would be the amino group that is common
to both kinds of substrates: amino acids and biogenic amines.
In fact, a mutant form of the serotonin transporter in which the
equivalent tyrosine (tyrosine 176) was replaced with cysteine
has decreased affinity for both serotonin and cocaine. More-
over, residual binding of a cocaine analog to this mutant is
blocked by chemical modification of the cysteine at position
176.3 The fact that Y140F-GAT-1 is totally void of transport
(Figs. 3 and 9B) suggests that it is the oxygen atom, which is
critical perhaps via the formation of a hydrogen bond with an
amine hydrogen.
Several amino acid residues/regions of the transporters have
been implicated in neurotransmitter binding. Tryptophan 222
of GAT-1 is one example (14), but recent data indicate a highly
reduced Vmax of GABA transport but an increased affinity for it
in tryptophan 222 mutants.4 The extracellular loops of GAT-1
also have been implicated (28), but it is very possible that they
function as a selectivity filter. In the dopamine transporter it
has been suggested that aspartic acid 79 located in the postu-
lated first transmembrane domain and serines 356 and 359
located in seventh are involved in binding of the amine (29).
These residues are conserved among the three biogenic amine
transporters, and it is possible, but not proven, that in these
cases they play, together with tyrosine 140, a role in neuro-
transmitter binding.
At this time it not possible to speculate on which other
residues might be involved in the liganding of GABA or other
transmitters. The theoretical model of the topology (4) may not
be in harmony with novel experimental data (20, 30). Until the
topology is firmly resolved, it is impossible to know which other
group might be located close by tyrosine 140. It is also difficult
to speculate on the identity of residues interacting with the
carboxyl group of GABA. One possibility is that the determi-
nants on some of the external loops are involved (28). These are
located in the carboxyl-terminal half of the transporter. Inter-
estingly, studies with chimeric biogenic amine transporters
indicate that regions involved in the recognition of the biogenic
amines are located in transmembrane domains 5–8 and even
more toward the carboxyl terminus (31–34). It is anticipated
that further mutagenesis studies focusing on these regions may
shed further light on the determinants for neurotransmitter
binding.
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